Clinico-pathological study and the effect of neoadjuvant chemotherapy in gastrointestinal stromal tumors

Date 28 June 2017
Event ESMO World Congress on Gastrointestinal Cancer 2017
Session ESMO World Congress on Gastrointestinal Cancer 2017
Topics GIST
Presenter Navneet Mishra Dr. Anchal
Citation Annals of Oncology (2017) 28 (suppl_3): iii13-iii136. 10.1093/annonc/mdx261
Authors N. Mishra Dr. Anchal, Y. Mishra Dr.
  • /

Abstract

Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal neoplasms of neurogenic or myogenic differentiation of the GastroIntestinal Tract (GIT). With an annual incidence of 11-14 per 1000000, they form 0.1%-3.0% of gastrointestinal malignant tumors. No sex predilection, mean age is 60years. GISTs can develop anywhere along the GIT from the esophagus to the rectum; however, stomach (60%) and small intestine (30%) are the most common locations and only 10% are found in the esophagus, mesentery, omentum, colon or rectum.